|
Volumn 182, Issue 2, 2005, Pages 318-319
|
Unexpected placebo response in premenstrual dysphoric disorder: Implication of endogenous opioids
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BETA ENDORPHIN;
ESTRADIOL;
FOLLITROPIN;
LUTEINIZING HORMONE;
NALMEFENE;
OPIATE;
OPIATE ANTAGONIST;
PLACEBO;
PROGESTERONE;
ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD;
ADDICTION;
BODY MASS;
CLINICAL ARTICLE;
COMPARATIVE STUDY;
CONTROLLED STUDY;
DISTRESS SYNDROME;
ESTRADIOL BLOOD LEVEL;
FEMALE;
FOLLICULAR PHASE;
FOLLITROPIN BLOOD LEVEL;
HUMAN;
HYPOTHESIS;
INSOMNIA;
INTERVIEW;
LETTER;
LUTEINIZING HORMONE BLOOD LEVEL;
MENSTRUAL CYCLE;
MULTIVARIATE ANALYSIS OF VARIANCE;
PAIN;
PATHOPHYSIOLOGY;
PREMENSTRUAL DYSPHORIC DISORDER;
PRIORITY JOURNAL;
PROGESTERONE BLOOD LEVEL;
PSYCHIATRIST;
QUESTIONNAIRE;
RADIOIMMUNOASSAY;
SAMPLING;
SCORING SYSTEM;
SCREENING;
SIDE EFFECT;
BETA-ENDORPHIN;
DOUBLE-BLIND METHOD;
FEMALE;
HUMANS;
MOOD DISORDERS;
NALTREXONE;
OPIOID PEPTIDES;
PILOT PROJECTS;
PLACEBO EFFECT;
PREMENSTRUAL SYNDROME;
QUESTIONNAIRES;
|
EID: 26844492982
PISSN: 00333158
EISSN: None
Source Type: Journal
DOI: 10.1007/s00213-005-0090-8 Document Type: Letter |
Times cited : (9)
|
References (6)
|